Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Restructuring Costs (2023 - 2025)

Maravai Lifesciences Holdings has reported Restructuring Costs over the past 3 years, most recently at $10.4 million for Q4 2025.

  • Quarterly results put Restructuring Costs at $10.4 million for Q4 2025, up 173916.67% from a year ago — trailing twelve months through Dec 2025 was $17.8 million (up 1568.45% YoY), and the annual figure for FY2025 was $17.8 million, up 1568.45%.
  • Restructuring Costs for Q4 2025 was $10.4 million at Maravai Lifesciences Holdings, up from $7.4 million in the prior quarter.
  • Over the last five years, Restructuring Costs for MRVI hit a ceiling of $10.4 million in Q4 2025 and a floor of -$1.2 million in Q1 2024.
  • Median Restructuring Costs over the past 3 years was $6000.0 (2024), compared with a mean of $3.3 million.
  • Biggest five-year swings in Restructuring Costs: tumbled 99.91% in 2024 and later skyrocketed 184750.0% in 2025.
  • Maravai Lifesciences Holdings' Restructuring Costs stood at $6.5 million in 2023, then tumbled by 99.91% to $6000.0 in 2024, then surged by 173916.67% to $10.4 million in 2025.
  • The last three reported values for Restructuring Costs were $10.4 million (Q4 2025), $7.4 million (Q3 2025), and $6000.0 (Q4 2024) per Business Quant data.